Macquarie Group’s AbCellera Biologics ABCL Stock Holding History

Macquarie Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-119,399	Closed	-$353K	–	1653
2024 Q2	$353K	Hold	119,399	–	–	﹤0.01%	1508
2024 Q1	$541K	Hold	119,399	–	–	﹤0.01%	1437
2023 Q4	$682K	Hold	119,399	–	–	﹤0.01%	1440
2023 Q3	$549K	Hold	119,399	–	–	﹤0.01%	1433
2023 Q2	$771K	Hold	119,399	–	–	﹤0.01%	1399
2023 Q1	$900K	Hold	119,399	–	–	﹤0.01%	1374
2022 Q4	$1.21M	Buy	+119,399	New	+$1.38M	﹤0.01%	1363

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Macquarie Group's ABCL Position: Q3 2024 in Review

Macquarie Group sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 119,399 shares — an estimated $353K sold.

Macquarie Group first reported a position in ABCL in Q4 2022 and held it in 7 quarters. The position peaked at $1.21M in Q4 2022. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

Macquarie Group reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 119,399 AbCellera Biologics shares in Q3 2024, an estimated $353K.
Macquarie Group first reported a position in AbCellera Biologics in Q4 2022 and held it in 7 quarters.
Macquarie Group's AbCellera Biologics position peaked at $1.21M in Q4 2022.
139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.